A Comparison of Tiotropium 18µg, Once Daily and Ipratropium 40µg, 4 Times Daily in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults with Chronic Obstructive Pulmonary Disease

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Safety Study ◽

Double Blind ◽

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(12)70052-8 ◽

2013 ◽

Vol 1 (1) ◽

pp. 51-60 ◽

Cited By ~ 173

Author(s):

Claus F Vogelmeier ◽

Eric D Bateman ◽

John Pallante ◽

Vijay KT Alagappan ◽

Peter D'Andrea ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Parallel Group Study ◽

Parallel Group

Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(13)70200-5 ◽

2014 ◽

Vol 2 (1) ◽

pp. 63-72 ◽

Cited By ~ 51

Author(s):

Henrik Watz ◽

Helen Barnacle ◽

Benjamin F Hartley ◽

Robert Chan

Keyword(s):

Pulmonary Disease ◽

Controlled Trial ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

P38 Mapk Inhibitor ◽

Mapk Inhibitor

Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Phase 3 Efficacy and Safety Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2011.12.605 ◽

2012 ◽

Vol 129 (2) ◽

pp. AB75

Author(s):

D.E. Doherty ◽

E. Kerwin ◽

D.P. Tashkin ◽

C.E. Matiz-Bueno ◽

T. Shekar ◽

...

Keyword(s):

Pulmonary Disease ◽

Mometasone Furoate ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Safety Study ◽

Phase 3 ◽

Obstructive Pulmonary Disease

Efficacy and Safety of Once-Daily Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease: Results of Two Replicate Randomized 12-Week Studies

CHEST Journal ◽

10.1378/chest.2059234 ◽

2014 ◽

Vol 146 (4) ◽

pp. 340A ◽

Cited By ~ 2

Author(s):

Thomas Siler ◽

Edward Kerwin ◽

Ana Sousa ◽

Alison Donald ◽

Rehan Ali ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Fluticasone Furoate ◽

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s82829 ◽

2015 ◽

pp. 1513

Author(s):

Santanu Sannigrahi ◽

Tieying Sun ◽

Yijiang Huang ◽

Michael Humphries ◽

Lingyan Bai ◽

...

Keyword(s):

Pulmonary Disease ◽

Chinese Patients ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study

Clinical Therapeutics ◽

10.1016/j.clinthera.2005.05.009 ◽

2005 ◽

Vol 27 (5) ◽

pp. 531-542 ◽

Cited By ~ 19

Author(s):

Barry Make ◽

Nicola A. Hanania ◽

Richard ZuWallack ◽

Christopher Kalberg ◽

Amanda Emmett ◽

...

Keyword(s):

Fluticasone Propionate ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Double Blind ◽

Parallel Group Study ◽

Parallel Group

Faculty Opinions recommendation of Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718489447.793532747 ◽

2017 ◽

Author(s):

Ravi Kalhan ◽

Sharon R Rosenberg

Keyword(s):

Pulmonary Disease ◽

Controlled Study ◽

Chronic Obstructive ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Efficacy and Tolerability of Indacaterol 75 μg Once Daily in Patients Aged ≥40 Years With Chronic Obstructive Pulmonary Disease: Results From 2 Double-Blind, Placebo-Controlled 12-Week Studies

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.11.009 ◽

2011 ◽

Vol 33 (12) ◽

pp. 1974-1984 ◽

Cited By ~ 23

Author(s):

Edward M. Kerwin ◽

Mark H. Gotfried ◽

David Lawrence ◽

Cheryl Lassen ◽

Benjamin Kramer

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Respiratory Research ◽

10.1186/1465-9921-12-55 ◽

2011 ◽

Vol 12 (1) ◽

Cited By ~ 49

Author(s):

Paul W Jones ◽

Stephen I Rennard ◽

Alvar Agusti ◽

Pascal Chanez ◽

Helgo Magnussen ◽

...

Keyword(s):

Pulmonary Disease ◽

Chronic Obstructive ◽

Efficacy And Safety ◽

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s72650 ◽

2015 ◽

pp. 57 ◽

Cited By ~ 1

Author(s):

Santanu Sannigrahi ◽

Tieying Sun ◽

Yijiang Huang ◽

Michael Humphries ◽

Lingyan Bai ◽

...

Keyword(s):

Pulmonary Disease ◽

Chinese Patients ◽

Chronic Obstructive ◽

Efficacy And Safety ◽